Dunsire Takes XTuit Helm As First Targets Approach The Clinic
Executive Summary
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
You may also be interested in...
XTuit Believes Microenvironment Approach Will Yield Cancer And Fibrosis Therapies
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports